Clinical Trial Update: Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for amrubicin in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Amrubicin (amrubicin)

Snippet

Sponsor: Sumitomo Pharma Co., Ltd. | Conditions: Lung Cancer | Phase 3 | Status: COMPLETED